Systemic lupus erythematosus and rheumatoid arthritis

Genotype Total 
OR 
95% 
CI 
P-value 
PDCD1 +ve and PTPN22 +ve 
Nephritis 9 (6.3%) 
142 
No-nephritis 9 (2.8%) 
321 
2.35 
0.91-6.04 
0.0696 
Controls 25 (2.7%) 
918 
2.42 
1.10-5.29 
0.0229 
PDCD1 +ve and PTPN22 -ve 
Nephritis 21 (14.8%) 
142 
No-nephritis 27 (8.4%) 
321 
1.89 
1.02-3.47 
0.0379 
Controls 90 (9.8%) 
918 
1.60 
0.95-2.66 
0.0710 
PDCD1 -ve and PTPN22 +ve 
Nephritis 43 (30.3%) 
142 
No-nephritis 74 (23.1%) 
321 
1.45 
0.93-2.25 
0.0988 
Controls 181 (19.7%) 
918 
1.77 
1.19-2.62 
0.0041 
PDCD1 -ve and PTPN22 -ve 
Nephritis 69 (48.6%) 
142 
No-nephritis 208 (64.8%) 
321 
0.51 
0.34-0.76 
0.0010 
Controls 622 (67.8%) 
918 
0.45 
0.31-0.64 
0.000008 
In summary: The 
PTPN22
1858T allele was associated with SLE 
per se
and 
with a renal disorder independent of the 
PD1.3
A allele. 
- 48 -

---

17. Paper IV: 
PTPN22 
polymorphism and anti-cyclic citrullinated peptide 
antibodies in combination strongly predicts future onset of rheumatoid 
arthritis and has a specificity of 100% for the disease. 
PTPN22
could have implications in the humoral autoimmunity and the 
PTPN22
1858C/T polymorphism was investigated further in individuals who had 
donated blood samples prior to any symptoms of RA. The risk allele conferred a 
significant risk of developing RA (
χ
2 
= 15.21, p = 0.0001) (Table 15).
Table 15.
Frequencies of 
PTPN22
1858C/T genotypes and of the T allele in individuals who later 
develop RA (pre-patients) and in controls.